Skip to main content
. 2016 Nov 7;35(2):226–235. doi: 10.1200/JCO.2016.67.9258

Fig 1.

Fig 1.

Progression-free survival in patients with (A) mucosal melanoma and (B) cutaneous melanoma who received nivolumab (NIVO) alone, combination therapy of NIVO plus ipilimumab (NIVO+IPI), or ipilimumab alone (IPI). Symbols indicate censored observations. Hazard ratios in (A): 0.61 (95% CI, 0.39 to 0.96; NIVO v IPI; P = .116); 0.42 (95% CI, 0.23 to 0.75; combination therapy versus ipilimumab; P = .003). Hazard ratios in (B): 0.73 (95% CI, 0.61 to 0.87; NIVO v IPI; P = .04); 0.49 (95% CI, 0.40 to 0.61; NIVO+IPI; P < .0001).